This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Edgewise Therapeutics (EWTX)

Tipranks - Tipranks - Thu May 21, 7:24AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Maze Therapeutics, Inc. (MAZE) and Edgewise Therapeutics (EWTX) with bullish sentiments.

Meet Samuel – Your Personal Investing Prophet

Maze Therapeutics, Inc. (MAZE)

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $110.00. The company’s shares closed last Tuesday at $24.46.

According to TipRanks.com, Ghosh is a 4-star analyst with an average return of 14.3% and a 38.4% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, ACADIA Pharmaceuticals, and Annexon Biosciences. ;'>

Currently, the analyst consensus on Maze Therapeutics, Inc. is a Strong Buy with an average price target of $63.50, which is a 161.4% upside from current levels. In a report issued on May 12, TD Cowen also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

Edgewise Therapeutics (EWTX)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics today and set a price target of $52.00. The company’s shares closed last Tuesday at $31.43.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 17.6% and a 57.9% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Protagonist Therapeutics, and Madrigal Pharmaceuticals. ;'>

Edgewise Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $41.70, representing a 32.3% upside. In a report issued on May 7, TipRanks – DeepSeek also upgraded the stock to Buy with a $41.00 price target.

Read More on MAZE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).